KEYMED BIO-B (02162) released the 2024 fiscal year results, with a loss attributable to Shareholders of 0.515 billion yuan, an increase of 43.4% year-on-year.

KEYMED BIO-B (02162) announced its annual performance for the year ending December 31, 2024, with revenue of 0.428 billion yuan...

Zhitong FinanceMar 24 09:17 ET

Express News | KeyMed Biosciences FY Revenue RMB 36 Million

ReutersMar 24 09:05 ET

KEYMED BIO-B: ANNUAL RESULTS ANNOUNCEMENTFOR THE YEAR ENDED DECEMBER 31, 2024; ANDCHANGE OF COMPOSITION OFTHE NOMINATION COMMITTEE

HKEXMar 24 09:05 ET · Announcements

KEYMED BIO-B (02162.HK) plans to hold a Board of Directors meeting on March 24 to approve the annual performance.

On March 12, Gelonghui reported that KEYMED BIO-B (02162.HK) announced that it will hold a Board of Directors meeting on March 24, 2025 (Monday) to consider and approve the company's and its subsidiaries' performance for the year ending December 31, 2024, and its release, as well as to consider the distribution of a final dividend (if any).

Gelonghui FinanceMar 12 04:38 ET

KEYMED BIO-B: DATE OF BOARD MEETING

HKEXMar 12 04:33 ET · Announcements

Individual Investors Are Keymed Biosciences Inc.'s (HKG:2162) Biggest Owners and Were Rewarded After Market Cap Rose by HK$400m Last Week

Simply Wall StMar 7 19:14 ET